ArticleCNS neuroscience & therapeutics2025
The Quinazoline Derivative, QNZ, Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined targeting of VISTA and sorafenib activates T cell-mediated anti-tumor immunity via the NF-κB/TNF axis in hepatocellular carcinoma.BMC medicine · 2026Article
- The Quinazoline Derivative, QNZ, Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsMultiple Sclerosis (MS) is a neuroinflammatory and neurodegenerative disease affecting the central nervous system (CNS). Substantial evidence implicates a central role for CD4+ T cells in MS pathogenesis, particularly IFN-γ+ Th1 cells and IL-17+ Th17 cells. NF-κB plays an essential role in regulating the differentiation of Th1 and Th17 cells, which typically mediate inflammatory responses as self-triggers. QNZ is a highly selective inhibitor of NF-κB transcriptional activation. In this study, we assessed the impact of QNZ on CD4+ T-cell polarization in MS. Utilizing the experimental autoimmune encephalomyelitis (EAE) model, we investigated these aspects of MS.
methodEAE was induced in C57BL/6 female mice by active immunization with myelin oligodendrocyte glycoprotein (MOG)
resultsProphylactic administration of QNZ to EAE mice suppressed the differentiation of Th1 and Th17 cells and demyelination within the spinal cord. Notably, QNZ also reduced the proportion of IFN-γ+IL-17+ Th17.1 cells, potentially playing a critical role in MS pathogenesis.
conclusionsQuinazoline derivative QNZ could suppress neuroinflammation, alleviate the progression of EAE and be associated with reduced Th1 and Th17 immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.